enVVeno Medical Corp’s activist reporting persons now hold 0.00% after Braeden Lichti and Northstrive Fund II LP sold all their previously owned common stock. The amendment matters to investors because it ends the Schedule 13D position, with the document identifying the change as a final amendment and exit filing.

Key Highlights

  • Northstrive Fund II LP sold its previously owned common stock from September 11, 2026 to September 14, 2026.
  • Braeden Lichti is identified as Northstrive Fund II LP’s manager and as chief executive officer of Northstrive Companies Inc.
  • Lichti used personal funds for his purchases, while Northstrive Fund II LP used working capital.

EnVVeno Medical Corp (NASDAQ: NVNO) now has no shares held by activist reporting persons Braeden Lichti and Northstrive Fund II LP, leaving the reported position at 0.00%. The amendment identifies the change as a final amendment and exit filing for both parties.

Sales Leave No Reported Ownership

Northstrive Fund II LP completed sales of its previously owned common stock from September 11, 2026 to September 14, 2026. The stock carries a Par Value of $0.00001 per share. The amendment lists zero sole and shared power to vote or direct votes for Northstrive Fund II LP, alongside zero sole and shared power to dispose of or direct disposition of shares.

Final Amendment Closes Activist Position

The shares were held by Northstrive Fund II LP and Lichti. Lichti is the fund’s manager and is principally engaged as chief executive officer of Northstrive Companies Inc. while Northstrive Fund II LP invests in private and public securities. Lichti used personal funds to buy his shares, and the fund used Working Capital for its purchases. Lichti and the fund signed the amendment on September 15, 2026.